Prurigo Nodularis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Verified date | August 2023 |
Source | Celldex Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.
Status | Completed |
Enrollment | 24 |
Est. completion date | July 31, 2023 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: 1. Males and females, 18 - 75 years old. 2. Diagnosis of Prurigo Nodularis by a dermatologist at least 3 months prior to Screening with: 1. At least 20 PN nodules with bilateral distribution on both arms and/or both legs and/or both sides of the trunk at screening. 2. An Investigators Global Assessment (IGA) score for PN = 3 at screening and Baseline (Day 1). 3. Severe itch, defined as the mean of the daily worst itch NRS (WI-NRS) score of = 7 during the 7-day period immediately prior to initiation of study treatment. 4. Documented history of inadequate response to prescription topical medications or for whom topical medications are medically inadvisable. 5. Willing to apply a topical moisturizer (emollient) twice daily throughout the study. 6. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days afterwards after treatment. 7. Willing and able to complete a daily symptom electronic diary for the duration of the study and adhere to the study visit schedule. Key Exclusion Criteria: 1. PN due to neuropathy, psychiatric disorders or medications. 2. Unilateral lesions of prurigo (eg, only one arm affected) 3. Active unstable pruritic skin conditions in addition to PN. 4. Women who are pregnant or nursing. 5. Known hepatitis B or hepatitis C infection or active COVID-19 infection 6. Vaccination with a live vaccine within 2 months prior to study drug administration (subjects must agree to avoid vaccination during the study and for four months thereafter). NOTE: Inactivated vaccines are allowed such as seasonal influenza for injection. COVID-19 vaccination is allowed. 7. History of anaphylaxis. There are additional criteria that your study doctor will review with you to confirm you are eligible for the study. |
Country | Name | City | State |
---|---|---|---|
Germany | Charité Centrum für Innere Medizin und Dermatologie, Institute of Allergology (IFA) | Berlin | |
Germany | Katholisches Klinikum Bochum gGmbH, Dermatologische Studienambulanz | Bochum | |
Germany | Universitatsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik fur Dermatologie | Dresden | |
Germany | Universitätsklinikum Frankfurt Klinik für Dermatologie, Venerologie und Allergologie Klinische Forschung | Frankfurt | |
Germany | Universitätsklinikum Erlangen Hautklinik | Mainz | |
Germany | Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hautklinik, Clinical Research Center | Mainz | |
Germany | Universitaetsklinikum Muenster (UKM) - Klinik für Hautkrankheiten | Münster | |
Poland | MT Medic Specjalistyczna Praktyka Lekarska | Krosno | |
Poland | IP Clinic Sp. z o.o. | Lódz | |
Poland | Centrum Medyczne Ginemedica | Wroclaw | |
United States | University of New Mexico | Albuquerque | New Mexico |
United States | Center for Clinical Studies, LTD.LLP | Houston | Texas |
United States | University of Miami, Dermatology Clinical Trials Unit | Miami | Florida |
United States | Markowitz Medical/Optiskin | New York | New York |
United States | Central Sooner Research | Norman | Oklahoma |
United States | Desert Sky Dermatology | Tempe | Arizona |
United States | Revival Research Institute, LLC | Troy | Michigan |
Lead Sponsor | Collaborator |
---|---|
Celldex Therapeutics |
United States, Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability as assessed by the incidence and severity of adverse events | Safety and tolerability of multiple dose levels of CDX-0159 as determined by drug related adverse events | From Day 1 (first dose) to Day 169 (last follow-up visit) | |
Secondary | Pharmacokinetic evaluation | CDX-0159 serum concentrations will be measured at specified visits | From Day 1 (before first dose) to Day 169 (last follow-up visit) | |
Secondary | Clinical effect of CDX-0159 on pruritus | The mean percent change from baseline to Week 8 in the weekly average score of worst intensity itch per a numeric rating scale. The Worst Itch-Numerical Rating Scale (WI-NRS) ranges from 0 = "no itch" to 10 ="worst imaginable itch" for their worst intensity prurigo nodularis itch in the preceding 24-hr period. | From Day 1 (first dose) to Day 57 (week 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT00869089 -
Safety and Efficacy of CC-10004 for Prurigo Nodularis
|
Phase 2 | |
Completed |
NCT04501666 -
An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
|
Phase 3 | |
Completed |
NCT03181503 -
Safety and Efficacy of Nemolizumab in PN
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Completed |
NCT05061693 -
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
|
Phase 2 | |
Completed |
NCT03546816 -
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
|
Phase 3 | |
Recruiting |
NCT06293053 -
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
|
Phase 3 | |
Not yet recruiting |
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A | |
Completed |
NCT02174419 -
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
|
Phase 2/Phase 3 | |
Terminated |
NCT03540160 -
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
|
Phase 3 | |
Recruiting |
NCT06427122 -
Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life
|
N/A | |
Completed |
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 | |
Recruiting |
NCT05764161 -
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
|
Phase 3 | |
Completed |
NCT02196324 -
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
|
Phase 2 | |
Not yet recruiting |
NCT06424470 -
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
|
Phase 3 | |
Recruiting |
NCT03576287 -
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
|
Phase 1/Phase 2 | |
Completed |
NCT05052983 -
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
|
Phase 3 | |
Active, not recruiting |
NCT04204616 -
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
|
Phase 3 | |
Recruiting |
NCT06213831 -
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
|
Phase 1 |